References
- Milivojevic V, Milosavljevic T. Burden of gastroduodenal diseases from the global perspective. Curr Treat Options Gastroenterol. 2020 Jan;18(1):148–157.
- Lanas A, Chan FKL. Peptic ulcer disease. Lancet. 2017 Aug 5; 390(10094):613–624.
- Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther. 2009 May 1;29(9):938–946.
- Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017 Aug;153(2):420–429.
- Peptic ulcer disease: Epidemiology, etiology, and pathogenesis Massachusetts: Up to Date; 2020 [cited 2021 Feb 06]. Available from: https://www.uptodate.com/contents/peptic-ulcer-disease-epidemiology-etiology-and-pathogenesis
- Schaible A, Kienle P, et al. Peptic ulcer disease: Perforation. In: Bland KI, Büchler MW, Csendes Aeditors. General Surgery. London: Springer London; 2009. p. 519–524.
- Lin KJ, García Rodríguez LA, Hernández-Díaz S. Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates? Pharmacoepidemiol Drug Saf. 2011 Jul;20(7):718–728.
- Kavitt RT, Lipowska AM, Anyane-Yeboa A, et al. Diagnosis and treatment of peptic ulcer disease. Am J Med. 2019 Apr;132(4):447–456.
- Bose S, Guyer A, Long A, et al. Evaluation and management of hypersensitivity to proton pump inhibitors. Ann Allergy Asthma Immunol. 2013 Dec;111(6):452–457.
- Peptic ulcer disease: Clinical manifestations and diagnosis Massachusetts: Up to Date; 2020 [cited 2021 Feb 06]. Available from: https://www.uptodate.com/contents/peptic-ulcer-disease-clinical-manifestations-and-diagnosis
- El-Serag HB, Kao JY, Kanwal F, et al. Houston consensus conference on testing for helicobacter pylori infection in the United States. Clin Gastroenterol Hepatol. 2018 Jul;16(7):992–1002.e6.
- Talebi Bezmin AA. Diagnosis of helicobacter pylori using invasive and noninvasive approaches. J Pathog. 2018;2018:9064952.
- Malfertheiner P, Megraud F, O’Morain CA, et al. Management of helicobacter pylori infection-the maastricht V/Florence consensus report. Gut. 2017 Jan;66(1):6–30.
- Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN guidelines for the management of helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017 Jun;64(6):991–1003.
- Indications and diagnostic tests for Helicobacter pylori infection Massachusetts: Up to Date; 2020 [cited 2021 Feb 06]. Available from: https://www.uptodate.com/contents/peptic-ulcer-disease-clinical-manifestations-and-diagnosis
- Melcarne L, García-Iglesias P, Calvet X. Management of NSAID-associated peptic ulcer disease. Expert Rev Gastroenterol Hepatol. 2016 Jun;10(6):723–733.
- Zeind CS, Carvalho MG. Applied therapeutics: the clinical use of drugs. Eleventh ed. Philadelphia: Wolters Kluwer Health; 2018.
- Savarino V, Marabotto E, Zentilin P, et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol. 2018;Nov;11(11):1123–1134.
- Peptic ulcer disease: Treatment and secondary prevention Massachusetts: Up to Date; 2020 [cited 2021 Feb 06]. Available from: https://www.uptodate.com/contents/peptic-ulcer-disease-treatment-and-secondary-prevention
- Kamada T, Satoh K, Itoh T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. J Gastroenterol. 2021 Apr;56(4):303–322.
- Marelli S, Pace F. Rabeprazole for the treatment of acid-related disorders. Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):423–435.
- Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11(1):27–37.
- USFDA. AMOXIL maryland: Maryland; 2008 [cited 2021 Feb 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050542s24,050754s11,050760s10,050761s10lbl.pdf
- USFDA. BIAXIN® filmtab® maryland: u.s. food and drug administration; 2009 [cited 2021 Feb 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050662s042,050698s024,050775s013lbl.pdf
- USFDA. DORYX® (doxycycline hyclate) maryland: u.s. food and drug administration; 2008 [cited 2021 Feb 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050795s005lbl.pdf
- USFDA. LEVAQUIN® (levofloxacin) tablets maryland: u.s. food and drug administration; 1996 [cited 2021 Feb 13]. Available from: https://www.fda.gov/files/drugs/published/Levaquin-Label.pdf
- USFDA. FLAGYL®(metronidazole) capsules Maryland: u.S. Food and Drug Administration; 2013 [cited 2021 Feb 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020334s008lbl.pdf
- USFDA. Flagyl® metronidazole tablets maryland: u.s. food and drug administration; 2010 [cited 2021 Feb 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/012623s061lbl.pdf
- USFDA. ALINIA® (nitazoxanide) maryland: u.s. food and drug administration; 2016 [cited 2021 Febraury 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021497s001,021498s004lbl.pdf
- USFDA. Rifabutin capsules maryland: u.s. food and drug administration; 2008 [cited 2021 Feb 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050689s016lbl.pdf
- Tetracyclines Massachusetts Up To Date 2021 [cited 2021 Feb 13]. Available from: https://www.uptodate.com/contents/tetracyclines#H5
- USFDA. Tindamax (tinidazole tablets) maryland: u.s. food and drug administration; 2004 [cited 2021 Feb 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21618_tindamax_lbl.pdf
- Ji X-Q, Du J-F, Chen G, et al. Efficacy of ilaprazole in the treatment of duodenal ulcers: a meta-analysis. World J Gastroenterol. 2014;20(17):5119–5123.
- Pu J, Wang F, Tang W, et al. Biotransformation of ilaprazole in human liver microsomes and human: Role of CYP3A4 in ilaprazole clearance and drug-drug interaction. Drug Metab Dispos. 2018 Oct;46(10):1453–1461.
- Wang L, Zhou L, Lin S, et al. A new PPI, ilaprazole compared with omeprazole in the treatment of duodenal ulcer: a randomized double-blind multicenter trial. J Clin Gastroenterol. 2011 Apr;45(4):322–329.
- Wang L, Zhou L, Hu H, et al. Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial. Curr Med Res Opin. 2012 Jan;28(1):101–109.
- Fan L, Xianghong Q, Ling W, et al. Ilaprazole compared with rabeprazole in the treatment of duodenal ulcer: a randomized, double-blind, active-controlled, multicenter study. J Clin Gastroenterol. 2019 Oct;53(9):641–647.
- Karaca RO, Kalkisim S, Altinbas A, et al. Effects of genetic polymorphisms of cytochrome P450 enzymes and MDR1 transporter on pantoprazole metabolism and helicobacter pylori eradication. Basic Clin Pharmacol Toxicol. 2017 Feb;120(2):199–206.
- Yu L-Y, Sun L-N, Zhang X-H, et al. A review of the novel application and potential adverse effects of proton pump inhibitors. Adv Ther. 2017;34(5):1070–1086.
- Aronson JK. Inhibiting the proton pump: mechanisms, benefits, harms, and questions. BMC Med. 2016 Nov 9;14(1):172.
- Schnoll-Sussman F, Niec R, Katz PO. Proton pump inhibitors: the good, bad, and ugly. Gastrointest Endosc Clin N Am. 2020 Apr;30(2):239–251.
- Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018 Apr;3(4):231–241.
- Waldum HL, Ø S, Fossmark R. Proton pump inhibitors (PPIs) may cause gastric cancer - clinical consequences. Scand J Gastroenterol. 2018 Jun;53(6):639–642.
- Nehra AK, Alexander JA, Loftus CG, et al. Proton pump inhibitors: review of emerging concerns. Mayo Clin Proc. 2018 Feb;93(2):240–246.
- Imhann F, Vich Vila A, Bonder MJ, et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes. 2017;8(4):351–358.
- Poly TN, Islam MM, Yang HC, et al. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019 Jan;30(1):103–114.
- Minalyan A, Gabrielyan L, Scott D, et al. The gastric and intestinal microbiome: Role of proton pump inhibitors. Curr Gastroenterol Rep. 2017;19(8): 42-42.
- Chrysant SG. Proton pump inhibitor-induced hypomagnesemia complicated with serious cardiac arrhythmias. Expert Rev Cardiovasc Ther. 2019 May;17(5):345–351.
- Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders Massachusetts Up to Date; 2020 [cited 2021 Feb 13]. Available from: https://www.uptodate.com/contents/proton-pump-inhibitors-overview-of-use-and-adverse-effects-in-the-treatment-of-acid-related-disorders
- Nguyen CT, Davis KA, Nisly SA, et al. Treatment of helicobacter pylori in special patient populations. Pharmacotherapy. 2019 Oct;39(10):1012–1022.
- Tarhini M, Fayyad-Kazan M, Fayyad-Kazan H, et al. First-line treatment of helicobacter pylori in lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy. Microb Pathog. 2018;117:23–26.
- Attia TZ, Yamashita T, Tsujino H, et al. Effect of drug combination on omeprazole metabolism by cytochrome P450 2C19 in helicobacter pylori eradication therapy. Chem Pharm Bull (Tokyo). 2019;67(8):810–815.
- Haddadi MH, Negahdari B, Asadolahi R, et al. Helicobacter pylori antibiotic resistance and correlation with cagA motifs and homB gene. Postgrad Med. 2020 Aug;132(6):512–520.
- Lamont JT Bacteriology and epidemiology of helicobacter pylori infection massachusetts: Up to date; 2020 [cited 2021 Feb 06]. Available from: https://www.uptodate.com/contents/bacteriology-and-epidemiology-of-helicobacter-pylori-infection
- Karpiński TM, Andrzejewska E, Eder P, et al. Evaluation of antimicrobial resistance of helicobacter pylori in the last 15 years in west poland. Acta Microbiol Immunol Hung. 2015 Sep;62(3):287–293.
- Ferenc S, Gnus J, Kościelna M, et al. High antibiotic resistance of Helicobacter pylori and its effect on tailored and empiric eradication of the organism in Lower Silesia, Poland. Helicobacter. 2017 Apr;22(2):e12365.
- Liu DS, Wang YH, Zeng ZR, et al. Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. Clin Microbiol Infect. 2018 Jul;24(7):780.e5–780.e8.
- Raymond J, Lamarque D, Kalach N, et al. High level of antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter. 2010 Feb;15(1):21–27.
- Siavoshi F, Saniee P, Malekzadeh R. Effective antimicrobial activity of rifabutin against multidrug-resistant Helicobacter pylori. Helicobacter. 2018 Dec;23(6):e12531.
- Ram MR, Teh X, Rajakumar T, et al. Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy. J Antimicrob Chemother. 2019 Jan 1;74(1):11–16.
- Hong J, Shu X, Liu D, et al. Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection: an open-label, randomized, single-centre clinical trial. J Antimicrob Chemother. 2016 Aug;71(8):2280–2285.
- Gawrońska-Szklarz B, Siuda A, Kurzawski M, et al. Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole. Eur J Clin Pharmacol. 2010 Jul;66(7):681–687.
- Zhang L, Mei Q, Li QS, et al. The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people. J Clin Pharm Ther. 2010 Dec;35(6):713–722.
- Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance. World J Gastroenterol. 2014;20(29):9898–9911.
- Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017 Feb;112(2):212–239.
- Lu HH, Lai FP, Lo HY, et al. Increasing antimicrobial resistance to clarithromycin and metronidazole in pediatric Helicobacter pylori infection in southern Taiwan: a comparison between two decades. Helicobacter. 2019 Oct;24(5):e12633.
- Nijevitch AA, Idrisov B, Akhmadeeva EN, et al. Choosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance. Curr Pharm Des. 2014;20(28):4510–4516.
- Fallone CA, Chiba N, van Zanten SV, et al. The toronto consensus for the treatment of helicobacter pylori infection in adults. Gastroenterology. 2016 Jul;151(1):51–69.e14.
- Saleem N, Howden CW. Update on the management of helicobacter pylori infection. In: Current treatment options in gastroenterology. 2020. p. 1–12.
- Treatment regimens for Helicobacter pylori Massachusetts: Up to Date; 2020 [cited 2021 Feb 06]. Available from: https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori
- Fakheri H, Taghvaei T, Hosseini V, et al. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial. Helicobacter. 2012 Feb;17(1):43–48.
- Valooran GJ, Kate V, Jagdish S, et al. Sequential therapy versus standard triple drug therapy for eradication of Helicobacter pylori in patients with perforated duodenal ulcer following simple closure. Scand J Gastroenterol. 2011 Sep;46(9):1045–1050.
- Choi HS, et al. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. World J Gastroenterol. 2012;18(19):2377–2382.
- Javid G, Zargar SA, Bhat K, et al. Efficacy and safety of sequential therapy versus standard triple therapy in Helicobacter pylori eradication in Kashmir India: a randomized comparative trial. Indian J Gastroenterol. 2013 May;32(3):190–194.
- Chan -C-C, Chien N-H, Lee C-L, et al. Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia. BMC Gastroenterol. 2015;15(1): 170-170. DOI:https://doi.org/10.1186/s12876-015-0401-4
- Basu PP, Rayapudi K, Pacana T, et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol. 2011 Nov;106(11):1970–1975.
- Xie Y, Pan X, Li Y, et al. New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial. J Antimicrob Chemother. 2018 Jun 1;73(6):1681–1687.
- Xie Y, Zhu Z, Wang J, et al. Ten-day quadruple therapy comprising low-dose rabeprazole, bismuth, amoxicillin, and tetracycline is an effective and safe first-line treatment for helicobacter pylori infection in a population with high antibiotic resistance: a prospective, multicenter, randomized, parallel-controlled clinical trial in China. Antimicrob Agents Chemother. 2018 Sep;62(9):e00432–18.
- Salmanroghani H, Mirvakili M, Baghbanian M, et al. Efficacy and tolerability of two quadruple regimens: bismuth, omeprazole, metronidazole with amoxicillin or tetracycline as first-line treatment for eradication of helicobacter pylori in patients with duodenal ulcer: a randomized clinical trial. PloS One. 2018;13(6):e0197096.
- Saha SK, Saha SK, Masud H, et al. To compare the efficacy of triple therapy with furazolidone, amoxicillin and omeprazole for two weeks and three weeks in the eradication of Helicobacter pylori in Bangladeshi duodenal ulcer patients. Bangladesh Med Res Counc Bull. 1970 Dec;37(3):83–87.
- Lim JH, et al. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection. World J Gastroenterol. 2015 Dec 14;21(46):13124–13131.
- Amoxicillin: Drug information Massachusetts: UpToDate; [ cited 2021 17 February]. Available from: https://uptodatefree.ir/topic.htm?path=amoxicillin-drug-information
- Amoxicillin: Patient drug information Massachusetts: UpToDate; [ cited 2021 17 February]. Available from: https://uptodatefree.ir/topic.htm?path=amoxicillin-patient-drug-information
- Bismuth subsalicylate: Drug information Massachusetts: UpToDate; 2021 [cited 2021 Feb 17]. Available from: https://uptodatefree.ir/topic.htm?path=bismuth-subsalicylate-drug-information
- Bismuth subsalicylate: Patient drug information Massachusetts: UpToDate; 2021 [cited 2021 Feb 17]. Available from: https://uptodatefree.ir/topic.htm?path=bismuth-subsalicylate-patient-drug-information
- Clarithromycin: Drug information massachusetts: UpToDate.
- Clarithromycin: Patient drug information Massachusetts: UpToDate; [ cited 2021 17 February]. Available from: https://uptodatefree.ir/topic.htm?path=clarithromycin-patient-drug-information
- Doxycycline: Drug information Massachusetts: UpToDate; [ cited 2021 17 February]. Available from: https://uptodatefree.ir/topic.htm?path=doxycycline-drug-information
- Doxycycline: Patient drug information Massachusetts: UpToDate; [ cited 2021 17 February]. Available from: https://uptodatefree.ir/topic.htm?path=doxycycline-patient-drug-information
- Levofloxacin (systemic): Drug information Massachusetts: UpToDate; [ cited 2021 17 February]. Available from: https://uptodatefree.ir/topic.htm?path=levofloxacin-systemic-drug-information
- Levofloxacin (systemic): Patient drug information Massachusetts: UpToDate; [ cited 2021 17 February]. Available from: https://uptodatefree.ir/topic.htm?path=levofloxacin-systemic-patient-drug-information
- Metronidazole (systemic): Drug information Massachusetts: UpToDate; [ cited 2021 17 February]. Available from: https://uptodatefree.ir/topic.htm?path=metronidazole-systemic-drug-information
- Metronidazole (systemic): Patient drug information Massachusetts: UpToDate; [ cited 2021 17 February]. Available from: https://uptodatefree.ir/topic.htm?path=metronidazole-systemic-patient-drug-information
- Nitazoxanide: Drug information Massachusetts: UpToDate; [ cited 2021 17 February]. Available from: https://uptodatefree.ir/topic.htm?path=nitazoxanide-drug-information
- Nitazoxanide: Patient drug information Massachusetts: UpToDate; [ cited 2021 17 February]. Available from: https://uptodatefree.ir/topic.htm?path=nitazoxanide-patient-drug-information
- Rifabutin: Drug information Massachusetts: UpToDate; [ cited 2021 17 February]. Available from: https://uptodatefree.ir/topic.htm?path=rifabutin-drug-information
- Rifabutin: Patient drug information Massachusetts: UpToDate; [ cited 2021 17 February]. Available from: https://uptodatefree.ir/topic.htm?path=rifabutin-patient-drug-information
- Tetracycline: Drug information Massachusetts: UpToDate; [ cited 2021 17 Februay]. Available from: https://uptodatefree.ir/topic.htm?path=tetracycline-drug-information
- Tetracycline: Patient drug information: UpToDate; [ cited 2021 17 February]. Available from: https://uptodatefree.ir/topic.htm?path=tetracycline-patient-drug-information
- Tinidazole: Drug information Massachusetts: UpToDate; [ cited 2021 17 February]. Available from: https://uptodatefree.ir/topic.htm?path=tinidazole-drug-information
- Tinidazole: Patient drug information Massachusetts: UpToDate; [ cited 2021 17 February]. Available from: https://uptodatefree.ir/topic.htm?path=tinidazole-patient-drug-information
- Murakami K, Okimoto T, Kodama M, et al. Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study. Scand J Gastroenterol. 2011 Mar;46(3):287–292.
- Yang X, Li Y, Sun Y, et al. Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases. Dig Dis Sci. 2018 Feb;63(2):302–311.
- Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials. Aliment Pharmacol Ther. 2017;45(2):240–252.
- Ashida K, Honda Y, Sanada K, et al. The safety and effectiveness of vonoprazan-based Helicobacter pylori eradication therapy; a prospective post-marketing surveillance. Expert Opin Drug Saf. 2019 Dec;18(12):1255–1261.
- Organisation WG. World gastroenterology organisation global guidelines: probiotics and prebiotics wisconsin, United States: World gastroenterology organisation 2017 [cited 2021 May 03]. Available from: https://www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-english
- Eslami M, Yousefi B, Kokhaei P, et al. Are probiotics useful for therapy of Helicobacter pylori diseases? Comp Immunol Microbiol Infect Dis. 2019;64:99–108.
- Mousavi T, Nikfar S, Abdollahi M. An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndrome. Expert Opin Drug Metab Toxicol. 2020 Jul;16(7):583–604.
- Daniali M, Nikfar S, Abdollahi M. Antibiotic resistance propagation through probiotics. Expert Opin Drug Metab Toxicol. 2020 Dec;16(12):1207–1215.
- Boltin D. Probiotics in Helicobacter pylori-induced peptic ulcer disease. Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):99–109.
- McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018 Oct 18;379(16):1509–1518.
- Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31;382(9894):769–779.
- García Rodríguez LA, Cattaruzzi C, Troncon MG, et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Internal Med. 1998 Jan 12;158(1):33–39.
- Strom BL, Berlin JA, Kinman JL, et al. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. Jama. 1996 Feb 7;275(5):376–382.
- Sugano K, Kontani T, Katsuo S, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2012 May;47(5):540–552.
- Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009 Mar;104(3):728–738.
- Masclee GM, Valkhoff VE, Coloma PM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology. 2014 Oct;147(4):784–792.e9. quiz e13-4.
- Yuan JQ, Tsoi KK, Yang M, et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther. 2016 Jun;43(12):1262–1275.
- Goldstein JL, Hochberg MC, Fort JG, et al. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther. 2010 Aug;32(3):401–413.
- Sostek MB, Fort JG, Estborn L, et al. Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers. Curr Med Res Opin. 2011 Apr;27(4):847–854.
- Laine L, Kivitz AJ, Bello AE, et al. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol. 2012 Mar;107(3):379–386.
- Deeks ED, Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy. Clin Drug Investig. 2013 Sep; 33(9):689–697.
- Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American college of cardiology foundation task force on clinical expert consensus documents. Circulation. 2008 Oct 28;118(18):1894–1909.
- NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity Massachusetts: Up to Date; 2019 [cited 2021 Feb 06]. Available from: https://www.uptodate.com/contents/nsaids-including-aspirin-primary-prevention-of-gastroduodenal-toxicity
- NSAIDs (including aspirin): Treatment of gastroduodenal toxicity Massachusetts: Up to Date; 2020 [cited 2021 Feb 06]. Available from: https://www.uptodate.com/contents/nsaids-including-aspirin-treatment-of-gastroduodenal-toxicity
- Chung CS, Chiang TH, Lee YC. A systematic approach for the diagnosis and treatment of idiopathic peptic ulcers. Korean J Intern Med. 2015 Sep;30(5):559–570.
- Lau JY, Sung J, Hill C, et al. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion. 2011;84(2):102–113.
- Vakil NB Unusual causes of peptic ulcer disease 2020 [cited 2021 Apr 30]. Available from: https://www.uptodate.com/contents/unusual-causes-of-peptic-ulcer-disease